Healthcare Cost

Oncology Drugs Dominate Medical Benefit Spend

May 18th 2022, 1:20pm

Article

Across commercial insurance, Medicare, and Medicaid populations, oncology is the top category of spend, and the drug pipeline has increasing specific and complex therapies.

Contributor: The Convergence of Value-Based Care and Lab Testing Growth

May 17th 2022, 5:15pm

Article

Today, health plans are shifting dollars to more value-based contracts along with investments in population health management. Digitizing lab results across all care settings and unlocking the potential of lab values can help health plans reach the Triple Aim of improving the patient experience, improving the health of populations, and reducing the per-member cost of health care.

RAND Report Assesses Hospital Prices Paid by Employers, Private Insurers

May 17th 2022, 4:00pm

Article

The report details totals paid to hospitals by private insurers and providers and compares the sums with a Medicare benchmark.

Greater Biologic Persistence, Adherence Achieved With Ixekizumab for Psoriasis

May 16th 2022, 7:45pm

Article

Significantly greater persistence, adherence, and time on monotherapy was achieved with the use of ixekizumab vs the biologics adalimumab, etanercept, secukinumab, and ustekinumab, in the treatment of moderate to severe psoriasis.

Walgreens’ Ray Tancredi Weighs in on Expensive Hemophilia Gene Therapies in the Pipeline

May 13th 2022, 5:59pm

Video

Gene therapies in the pipeline to treat hemophilia will be very expensive, but they also seem to be very efficacious, and multiple could hit the market between now and 2024, said Ray Tancredi, RPh, MBA, CSP, divisional vice president, specialty pharmacy development and brand Rx/vaccine purchasing, Walgreens.

Jayson Slotnik Discusses Using Payment Models to Address Health Equity

May 13th 2022, 2:35pm

Video

While CMS has started making changes to address health equity through policy and payment models, commercial plans are waiting to see the outcomes before they follow suit, said Jayson Slotnik, partner, Health Policy Strategies, Inc.

Physician Prices and Low-Value Services: Evidence From General Internal Medicine

May 12th 2022, 4:00pm

Article

This study found extensive variation in general internal medicine physician prices and that high-priced physicians provided fewer low-value services but had higher spending on these services.

Managed Care Has a Key Role in Biosimilar Adoption, Says Cardinal's Oskouei

May 12th 2022, 1:17pm

Article

Biosimilar adoption can be accelerated or stymied depending on actions taken by the managed care space, explained Sonia Oskouei, PharmD, vice president, biosimilars, Cardinal Health, during a session at Asembia’s Specialty Pharmacy Summit.

IQVIA’s Doug Long: Adalimumab Biosimilars Provide More Opportunity for Price Discounts

May 10th 2022, 4:52pm

Video

The impact that the adalimumab biosimilars will have in 2023 is going to depend on when they all get to market, said Doug Long, MBA, vice president, industry relations, IQVIA.

What We're Reading: Senate to Vote on Abortion Rights Bill; Hospitals Raising Treatment Costs; Baby Formula Shortage Worsening

May 9th 2022, 2:40pm

Article

US Senate to vote this week on legislation seeking to codify abortion rights into law; hospitals aiming to raise treatment prices in response to increasing nurse salaries; shortage of infant formula worsening nationwide.